A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis.

Steven R FeldmanJoanna NarbuttGiampiero GirolomoniJan BrzezickiNataliya ReznichenkoMaria Agnieszka Zegadło-MylikGrazyna PulkaMagdalena Dmowska-StecewiczElżbieta KłujszoDmytro RekalovLidia RajzerJiyoon LeeMinkyung LeeYoung Hee Rho

Published in: Journal of the American Academy of Dermatology (2024)

SB17 was clinically biosimilar to UST up to week 28.

Keyphrases

phase iii
placebo controlled
double blind
clinical trial
open label
phase ii
coronary artery disease
high intensity
early onset
drug induced